Escalation of Mechanical Support in Post-MI Cardiogenic Shock
62-year-old man with anterior STEMI treated with PCI 18 hours ago develops hypotension. He is intubated and on norepinephrine 0.15 mcg/kg/min and dobutamine 5 mcg/kg/min. BP 82/50, HR 115, lactate 5.2 mmol/L, urine output 15 mL/h, ScvO2 50%. Echo: LVEF 25%, severe anterior akinesis, no tamponade, no significant MR, RV normal. PA catheter: RA 14 mmHg, PCWP 24 mmHg, CI 1.6 L/min/m2, PVR 2.8 WU. ECG shows sinus tachycardia with Q waves V1-V4. Troponin peak 80 ng/mL, creatinine 1.8 mg/dL, pH 7.28. He has no prior heart failure and no advanced directive.
1. How would you stage his shock and decide between continued drugs, IABP, and a microaxial flow pump?
Read the worked answer
He is in SCAI stage D cardiogenic shock: hypoperfusion with lactate 5.2, oliguria, low ScvO2, CI 1.6, and escalating pressors after revascularization. IABP alone is unlikely to provide enough forward flow and has not improved mortality in randomized trials; it may be considered for mechanical complications or as a bridge, but not as definitive escalation here. A microaxial flow pump (Impella CP) is reasonable if there is no significant aortic regurgitation, no LV thrombus, and no severe RV failure, because his RV appears normal. The key judgment is timing: escalate before irreversible end-organ failure, not after lactate >10 and anuria. If he deteriorates with hypoxemia or biventricular failure, venoarterial ECMO is the next step. Continue revascularization optimization and treat arrhythmias.
2. What pre-support assessment and concurrent therapies would you prioritize?
Read the worked answer
Before Impella, obtain urgent echo to rule out tamponade, severe MR, VSD, and aortic insufficiency; confirm access vessels and valve anatomy. Check for LV thrombus because apical akinesis predisposes to it. Continue norepinephrine to maintain MAP about 65 mmHg and dobutamine for inotropy, but avoid excessive pressors that increase afterload. Treat acidosis and hypoxemia, start renal replacement if oliguria persists, and correct electrolytes. Ensure dual antiplatelet therapy and anticoagulation are managed with the device team. Consider invasive hemodynamic monitoring and serial lactate. A code status and goals-of-care discussion should occur early with the family, because mortality remains high even with support.
3. When would you consider transplant or durable LVAD, and how would you wean support?
Read the worked answer
Transplant evaluation is not appropriate during acute shock with multiorgan failure. If he survives but has persistent LVEF <25% and INTERMACS 3-4 symptoms after 72-96 hours, he can be evaluated for durable LVAD or transplant once neurologically intact and infection-free. Weaning from Impella should be guided by native LV recovery on echo, stable MAP on low pressors, lactate clearance, and urine output; perform a flow reduction trial with echo and PA catheter. If he cannot be weaned, escalate to durable support or transplant listing depending on candidacy. If he remains in refractory shock with no recovery, palliative care should be involved. His acute MI and prior normal heart make recovery more likely than in chronic cardiomyopathy, so give time before committing to destination therapy.